Sugammadex in anesthesia practice

Bibliography

• Egan TD, Kern SE, Johnson KB, The pharmacokinetics and pharmacodynamics of propofol in a modified cyclodextrin formulation (Captisol ®) versus propofol in a lipid formulation (Diprivan ®): an electroencephalographic and hemodynamic study in a porcine model. Anesth Analg 2003;97:72-9
   PubMed Web of Science ®Google Scholar
• Bom A, Epemolu O, Hope F, Selective relaxant binding agents for reversal of neuromuscular blockade. Curr Opin Pharmacol 2007;7:298-302
   PubMed Web of Science ®Google Scholar
• Griffith HR, Johnson GE. The use of curare in general anesthesia. Anesthesiology 1942;3:418-20
   Google Scholar
• Duvaldestin P, Cunin P, Plaud B, French survey of neuromuscular relaxant use in anesthetic practice in adults. Ann Fr Anesth Rean 2008;27:483-9
   PubMedGoogle Scholar
• Chambers D, Paulden M, Paton F, Sugammadex for the reversal of muscle relaxation in general anaesthesia: a systematic review and economic assessment. Health Technol Assess 2010;14:1-211
   Web of Science ®Google Scholar
• Martyn JA, Richtsfeld M. Succinylcholine-induced hyperkalemia in acquired pathological states: etiologic factors and molecular mechanisms. Anesthesiology 2006;104:158-61
   PubMed Web of Science ®Google Scholar
• Gronert GA. Cardiac arrest after succinylcholine: mortality greater with rhabdomyolysis than upregulation. Anesthesiology 2001;94:523-30
   PubMedGoogle Scholar
• Berg H, Viby-Mogensen J, Engbaek J, Residual block is a risk factor for postoperative pulmonary complications. A prospective, randomized and blinded study of postoperative complication after atracurium, vecuronium and pancuronium. Acta Anaesth Scand 1997;41:1095-10
   PubMed Web of Science ®Google Scholar
• Plaud B, Debaene B, Donati F, Marty J. Residual paralysis after emergence from anesthesia. Anesthesiology 2010;112:1013-22
   PubMedGoogle Scholar
• Whittaker M. Plasma cholinesterase variants and the anesthetist. Anaesthesia 1980;35:174-97
   PubMed Web of Science ®Google Scholar
• Viby-Mogensen J. Clinical assessment of neuromuscular transmission. Br J Anaesth 1982;54:209-23
   PubMedGoogle Scholar
• Fuchs-Buder T, Claudius C, Skovgaard LT, Good clinical research practice in pharmacodynamic studies of neuromuscular blocking agents II: the Stockholm revision. Acta Anaesthesiol Scand 2007;51:789-808
   PubMed Web of Science ®Google Scholar
• Grayling M, Sweeney BP. Recovery from neuromuscular blockade: a survey of practice. Anaesthesia 2007;62:806-9
   PubMed Web of Science ®Google Scholar
• Debaene B, Plaud B, Dilly MP, Residual paralysis in the PACU after a single intubating dose of nondepolarizing relaxant with an intermediate duration of action. Anesthesiology 2003;98:1042-8
   PubMed Web of Science ®Google Scholar
• Mc Caul C, Tobin E, Boylan JF, Atracurium is associated with postoperative residual curarization. Br J Anaesth 2002;89:766-9
   PubMedGoogle Scholar
• Hayes AH, Mirakhur RK, Breslin DS, Postoperative residual block after intermediate-acting neuromuscular blocking drugs. Anaesthesia 2001;56:312-18
   PubMed Web of Science ®Google Scholar
• Kim KS, Lew SH, Cho HY, Residual paralysis induced by either vecuronium or rocuronium after reversal with pyridostigmine. Anesth Analg 2002;95:1656-60
   PubMedGoogle Scholar
• Murphy GS, Szokol JW, Marymont JH, Residual paralysis at the time of extubation. Anesth Analg 2005;100:1840-5
   PubMed Web of Science ®Google Scholar
• Cammu G, De Witte J, De Veylder J, Postoperative residual paralysis in outpatients versus inpatients. Anesth Analg 2006;102:426-9
   PubMed Web of Science ®Google Scholar
• Eriksson LI. Evidence-based practive and neuromuscular monitoring. It's time for routine quantitative assessment. Anesthesiology 2003;98:1037-9
   PubMed Web of Science ®Google Scholar
• Viby-Mogensen J, Jorgensen BC, Ording H. Residual curarization in the recovery room. Anesthesiology 1979;50:539-41
   PubMed Web of Science ®Google Scholar
• Eriksson LI, Sundman E, Olsson R, Functional assessment of the pharynx at rest and during swallowing in partially paralysed humans. Anesthesiology 1997;87:1035-43
   PubMed Web of Science ®Google Scholar
• Sundman E, Witt H, Olsson R, The incidence and mechanism of pharyngeal and upper esophageal dysfunction in partially paralyzed humans. Anesthesiology 2000;92:977-84
   PubMed Web of Science ®Google Scholar
• Claudius C, Viby-Mogensen J. Acceleromyography for use in scientific and clinical practice. A systematic review of evidence. Anesthesiology 2008;108:1117-40
   PubMedGoogle Scholar
• Baillard C, Bourdiau S, Le Toumelin P, Assessing residual neuromuscular blockade using accelerometry can be deceptive in postoperative awake patients. Anesth Analg 2004;98:854-7
   PubMed Web of Science ®Google Scholar
• Booij LHDJ. Cyclodextrins and the emergence of sugammadex. Anaesthesia 2009;64(Suppl 1):31-7
   PubMedGoogle Scholar
• Cheng CR, Sessler DI, Apfel CC. Does neostigmine administration produce a clinically important increase in postoperative nausea and vomiting? Anesth Analg 2005;101:1349-55
   PubMed Web of Science ®Google Scholar
• Bom A, Bradley M, Camero K, A novel concept of reversing neuromuscular block: chemical encapsulation of rocuronium bromide by a cyclodextrin-based synthetic host. Angew Chem Int Ed Engl 2002;41:266-70
   PubMed Web of Science ®Google Scholar
• Adam JM, Benett DJ, Bom A, Cyclodextrin-derived host molecules as reversal agents for the neuromuscular blocker rocuronium bromide:synthesis and structure activity-relationships. J Med Chem 2002;45:1806-16
   PubMed Web of Science ®Google Scholar
• Zhang MQ. Drug-specific cyclodextrins: the future of rapid neuromuscular block reversal? Drugs Future 2003;28:347-54
   Web of Science ®Google Scholar
• Epemolu O, Bom A, Hope F, Reversal of neuromuscular blockade and simultaneous increase in plasma rocuronium concentration after the intravenous infusion of the novel reversal agent Org 25969. Anesthesiology 2003;99:632-7
   PubMed Web of Science ®Google Scholar
• Gijsenbergh F, Ramael S, Houwing N, First human exposure of Org 25969, a novel agent to reverse the action of rocuronium bromide. Anesthesiology 2005;103:695-703
   PubMed Web of Science ®Google Scholar
• Sorgenfrei IF, Norrild K, Larsen PB, Reversal of rocuronium-induced neuromuscular block by the selective relaxant binding agent sugammadex. Anesthesiology 2006;104:667-74
   PubMed Web of Science ®Google Scholar
• Sparr HJ, Vermeyen KM, Beaufort A, Early reversal of profound rocuronium-induced neuromuscular blockade by sugammadex in a randomized multicenter study. Efficacy, safety and pharmacokinetics. Anesthesiology 2007;106:935-43
   PubMed Web of Science ®Google Scholar
• de Boer HD, Van Egmond J, Van de Pol F, Sugammadex,a new reversal agent for neuromuscular block induced by rocuronium in the anesthetized Rhesus monkey. Br J Anaesth 2006;96:473-9
   PubMed Web of Science ®Google Scholar
• Shields M, Giovanelli M, Mirakhur RK, Org25969 (sugammadex), a selective relaxant binding agent for antagonism of prolonged rocuronium-induced neuromuscular block. Br J Anaesth 2006;96:36-43
   PubMed Web of Science ®Google Scholar
• Vanacker BF, Vermeyen KM, Struys MMRF, Reversal of rocuronium-induced neuromuscular block with the novel drug sugammadex is equally effective under maintenance anesthesia with propofol or sevoflurane. Anesth Analg 2007;104:563-8
   PubMed Web of Science ®Google Scholar
• Rex C, Wagner S, Spies C, Reversal of neuromuscular blockade by sugammadex after continuous infusion of rocuronium in patients randomized to sevoflurane or propofol maintenance anesthesia. Anesthesiology 2009;111:30-5
   PubMed Web of Science ®Google Scholar
• Suy K, Morias K, Cammu G, Effective reversal of moderate rocuronium or vecuronium-induced neuromuscular block with sugammadex, a selective relaxant binding agent. Anesthesiology 2007;106:283-8
   PubMed Web of Science ®Google Scholar
• Khuenl-Brady KS, Wattwil M, Vanacker CK, Sugammadex provides faster reversal of vecuronium-induced neuromuscular blockade compared with neostigmine, a multicenter, randomized, controlled trial. Anesth Analg 2010;110:64-73
   PubMed Web of Science ®Google Scholar
• Flockton EA, Mastronardi P, Hunter JM, Reversal of rocuronium-induced neuromuscular block with sugammadex is faster than reversal of cisatracurium-induced block with neostigmine. Br J Anaesth 2008;100:622-30
   PubMed Web of Science ®Google Scholar
• Eleveld DJ, Kuizenga K, Proost JH, A temporary decrease in twitch response during reversal of rocuronium-induced muscle relaxation with a small dose of sugammadex. Anesth Analg 2007;104:582-4
   PubMed Web of Science ®Google Scholar
• Plaud B, Meretoja O, Hojmockel R, Reversal of rocuronium-induced neuromuscular blockade with sugammadex in pediatric and adult surgical patients. Anesthesiology 2009;110:284-94
   PubMed Web of Science ®Google Scholar
• Duvaldestin P, Kuizenga K, Saldien V, A randomized, dose-response study of sugammadex given for the reversal of deep rocuronium- or vecuronium-induced neuromuscular blockade under sevoflurane anesthesia. Anesth Analg 2010;110:74-82
   PubMed Web of Science ®Google Scholar
• Groudine SB, Soto R, Lien C, A randomized, dose-finding, phase II study of the selective relaxant binding drug, sugammadex, capable of safely reversing profound rocuronium-induced neuromuscular block. Anesth Analg 2007;104:555-62
   PubMed Web of Science ®Google Scholar
• MCCourt KC, Salmela L, Mirakhur RK, Comparison of rocuronium and suxamethonium for use during rapid sequence induction of anaesthesia. Anaesthesia 1998;53:867-71
   PubMed Web of Science ®Google Scholar
• FDA Anesthetic and Life Support Advisory Committee Meeting. Sugammadex Sodium Injection. (NDA 22-225). March 11, 2008. Briefing Document (Background Package). Organon USA. Available from: http://www.fda.gov/ohrms/dockets/ac/08/briefing/2008-4346b1-02-Organon.pdf. [Last accessed 4 August 2010]
   Google Scholar
• de Boer HD, Driessen JJ, Marcus MAE, Reversal of rocuronium-induced (1.2 mg/kg) profound neuromuscular block by sugammadex. Anesthesiology 2007;107:239-44
   PubMed Web of Science ®Google Scholar
• Puhringer FK, Rex C, Sielenkamper AW, Reversal of profound, high-dose rocuronium-induced neuromuscular blockade by sugammadex at two different time points. Anesthesiology 2008;109:188-97
   PubMed Web of Science ®Google Scholar
• Lee C, Jahr JS, Candiotti KA, Reversal of profund neuromuscular block by sugammadex administered three minutes after rocuronium: a comparison with spontaneous recovery from succinylcholine. Anesthesiology 2009;110:1020-5
   PubMed Web of Science ®Google Scholar
• Staals LM, Snoeck MMJ, Driessen JJ, Reduced clearance of rocuronium and sugammadex in patients with severe to end-stage renal failure: a pharmacokinetic study. Br J Anaesth 2010;104:31-9
   PubMed Web of Science ®Google Scholar
• Szenohradszky J, Fisher DM, Segredo N, Pharmacokinetics of rocuronium (ORG 9426) in patients with normal renal function or patients undergoing cadaveric renal transplantation. Anesthesiology 1992;77:899-904
   PubMedGoogle Scholar
• Cooper RA, Maddineni VR, Mirakhur RK, Pharmacokinetics of rocuronium bromide in patients with and without renal failure. Br J Anaesth 1993;11:43-4
   Google Scholar
• Proost JH, Eriksson LI, Mirakhur RK, Urinary, biliary and faecal excretion of rocuronium in humans. Br J Anaesth 2000;85:717-23
   PubMed Web of Science ®Google Scholar
• Cammu G, De Kam PJ, Demeyer I, Safety and tolerability of single intravenous doses of sugammadex administered simultaneously with rocuronium or vecuronium in healthy volunteers. Br J Anaesth 2008;100:373-9
   PubMed Web of Science ®Google Scholar
• de Kam PJ, van Kuijk J, Prohn M, Effects of sugammadex doses up to 32 mg/kg alone or in combination with rocuronium or vecuronium on QTc prolongation. A thorough QTc study. Clin Drug Investig 2010;30:599-611
   PubMed Web of Science ®Google Scholar
• A Randomized, double-blind, placebo-controlled, parallel-group study to evaluate the incidence of hypersensitivity after repeated single dose administrations of sugammadex in healthy subjects. Study P06042. Available from: http://clinicaltrials.gov/ct2/show/NCT00988065?term=sugammadex&rank=3 [Last accessed 4 August 2010]
   Google Scholar
• Bhananker SM, O'Donnell JT, Salemi JR, The risk of anaphylactic reactions to rocuronium in the United States is comparable to that of vecuronium:an analysis of Food and Drug Administration reporting of adverse events. Anest Analg 2005;101:819-22
   PubMed Web of Science ®Google Scholar
• Dewachter P, Mouton-Faivre C, Emala CW. Anaphylaxis and anesthesia. Controversies and new insights. Anesthesiology 2009;111:1141-50
   PubMed Web of Science ®Google Scholar
• Baillard C, Korinek AM, Galanton V, Anaphylaxis to rocuronium. Br J Anaesth 2002;88:600-2
   PubMedGoogle Scholar
• Harboe T, Guttormsen AB, Irgens A, Anaphylaxis during anesthesia in Norway:a six-year single-center follow-up study. Anesthesiology 2005;102:897-903
   PubMed Web of Science ®Google Scholar
• McNeil O, Kerridge RK, Boyle MJ. Review of procedures for investigation of anaesthesia-associated anaphylaxis in Newcastle, Australia. Anaesth Intens Care 2008;36:201-7
   PubMedGoogle Scholar
• Miller RD. Will succinylcholine ever disappear? Anesth Analg 2004;98:1674-5
   PubMedGoogle Scholar
• Lee C. Goodbye suxamethonium Anaesthesia 2009;64(Suppl 1):73-81
   PubMedGoogle Scholar
• Arbous MS, Meursing AEE, Van Kleef JW, Impact of anesthesia management characteristics on severe morbidity and mortality. Anesthesiology 2005;102:257-68
   PubMed Web of Science ®Google Scholar
• Blobner M, Eriksson LI, Scholz J, Reversal of rocuronium-induced neuromuscular blockade with sugammadex compared with neostigmine during sevoflurane anaesthesia: results of a randomised, controlled trial. Eur J Anaesthesiol 2010;27:874-81
   PubMed Web of Science ®Google Scholar
• Jones RK, Caldwell JE, Brull SJ, Soto RG. Reversal of profound rocuronium-induced blockade with sugammadex: a randomized comparison with neostigmine. Anesthesiology 2008;109:816-24
   PubMed Web of Science ®Google Scholar
• Lemmens HJ, El-Orbany MI, Berry J, Reversal of profound vecuronium-induced neuromuscular block under sevoflurane anesthesia: sugammadex versus neostigmine. BMC Anesthesiol 2010;10:15
   PubMedGoogle Scholar
• Sacan O, White PF, Tufanogullari B, Klein K. Sugammadex reversal of rocuronium-induced neuromuscular blockade: a comparison with neostigmine – glycopyrrolate and edrophonium – atropine. Anesth Analg 2007;104:569-74
   PubMed Web of Science ®Google Scholar
• Staals LM, Snoeck MMJ, Driessen JJ, Multicentre, parallel-group, comparative trial evaluating the efficacy and safety of sugammadex in patients with end-stage renal failure or normal renal function. Br J Anaesth 2008;101:492-7
   PubMed Web of Science ®Google Scholar